EXAMINE THIS REPORT ON HEMGENIX

Amount of suitable clients: CDEC talked over the uncertainty in the volume of people with reasonably critical to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who are classified as owning moderate or reasonable condition can have a significant bl